Dr. S. Moein Moghimi earned his Bachelor degree in Biochemistry with Honors from the University of Manchester (UK), and his Doctorate in Biochemistry/Immunobiology from Charing Cross and Westminster Medical School, Imperial College, London. Following postdoctoral training and a University Fellowship at the School of Pharmaceutical Sciences at Nottingham University (UK), he moved to the University of Brighton as a senior lecturer in Biopharmacy and Molecular Therapy. In 2008, Dr. Moghimi accepted as the chair of Nanomedicine at the University of Copenhagen (Denmark), where he currently heads the Nanomedicine Research Group at the School of Pharmacy, Faculty of Health and Medical Sciences. In 2009, he founded the Centre for Pharmaceutical Nanotechnology and Nanotoxicology (CPNN) at the NanoScience Centre of Copenhagen University through a multi-million dollar award by the Strategic Research Council of Denmark, where he acts in the capacity of centre director. Dr. Moghimi is also the honorary professor of Nanomedicine at the Multidisciplinary Research Center, Shantou University (China) and an elected fellow of the Institute of Nanotechnology in the UK. Since 2009, Dr. Moghimi has secured over US$13 million in competitive research funds in basic and applied nanomedicine research as the principal investigator and is currently a partner in two large-scale competitive European Commission FP-7 programs in translational nanomedicine/drug delivery, addressing Alzheimer’s disease and atherosclerosis with secured budgets of US$ 14.5 million and US$ 11 million, respectively. Dr. Moghimi’s research activities are focused on pharmaceutical nanoscience, nanotechnology in iMedicine, nanotoxicology and fundamental/translational nanomedicine in relation to cancer, neurodegenerative diseases, cardiovascular diseases, and immunological disorders. He has pioneered research in the design and surface engineering of nanoparticles and functional nanosystems for parenteral site-specific targeting/drug delivery and imaging modalities (e.g., splenotropic entities, lymphotropic agents, ‘phagocyte-resistant’ nanoparticles, cancer nanomedicine, cerebral endothelial-specific nanoparticle-fiber networks) as well as the molecular basis of nanomaterial immune toxicity, polymer cytotoxicity, and preventive measures. Dr. Moghimi serves as the associate editor of Nanomedicine: Nanotechnology, Biology and Medicine (Elsevier) and the Journal of Biomedical Nanotechnology, and sits on the editorial/advisory board of over 15 peer-reviewed international journals, including Advanced Drug Delivery Reviews, Nanomedicine-UK (Future Medicine), and Molecular and Cellular Therapies (BioMed Central). Dr. Moghimi has been a practicing consultant to numerous pharmaceutical, biotechnology, health and food industry companies as well as investment banks, management consultancy firms, and other entrepreneurial enterprises globally for over two decades. He is also a regularly invited assessor and expert evaluator in nanomedicine and pharmaceutical science research centers/research projects for governmental bodies, research councils, and private organizations worldwide (> 50 establishments in 20 countries). As a frequent keynote and guest speaker at many international conferences and organizations, as well as being regular conference chair and organizer, Dr. Moghimi has given over 300 invited speeches and lectures. He has published over 170 peer-reviewed articles in prestigious international journals and book chapters, and is the inventor of many patents.
Dr. S. Moein Moghimi's research interests focus on: Brain targeting Cancer Complement system Nanomedicine Nanotoxicology